With the recent success of clinical trials assessing the efficacy of MDMA-assisted psychotherapy for PTSD and the numerous other studies on the use of psychedelics as therapeutics, focus has begun to shift towards their approval by regulatory agencies. As with any new drug that affects the central nervous system (CNS), both MDMA and psychedelics such as psilocybin will need to be evaluated for…


Previous articlePT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits
Next articleWebinar: Psychedelic Integration and Depth Relational Process